Vor Biopharma Inc. Operating Lease Liability
Vor Biopharma Inc. (VOR) had Operating Lease Liability of $2.88 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-11
- 2026-06-30: Operating Lease, Liability $2.88M.
- 2026-03-31: Operating Lease, Liability $2.94M.
- 2025-12-31: Operating Lease, Liability $3.00M.
- 2025-09-30: Operating Lease, Liability $3.06M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $2.88M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.94M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $3.00M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $3.06M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-12 |
| 2025-03-31 | $30.78M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $31.83M 10-K · filed 2026-03-30 |
| 2024-09-30 | $32.85M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $33.82M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $34.74M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $35.66M 10-K · filed 2025-03-20 |
| 2023-09-30 | $36.60M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $37.51M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $38.45M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $38.91M 10-K · filed 2024-03-20 |
| 2022-09-30 | $40.29M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $41.81M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $28.96M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $18.01M 10-K · filed 2023-03-23 |
| 2021-09-30 | $17.61M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $17.89M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $18.28M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $18.29M 10-K · filed 2022-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |